SCHEMBL14729696

SCHEMBL14729696

Fc1ccc(-c2cc(OCc3ccccc3)c(OCc3ccccc3)nn2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.43
NPC1 O15118 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PTGER1 P34995 2/20 0.39
KMO O15229 1/20 0.39
ALOX5AP P20292 2/20 0.39
CTSV O60911 1/20 0.39
CTSL P07711 1/20 0.39
KDM1A O60341 3/20 0.39
SQOR Q9Y6N5 1/20 0.39
ERN1 O75460 1/20 0.38
TOP1 P11387 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14729659 0.88 KMO (0.42) NPC1MEN1POLBRAB9AKMT2A
SCHEMBL14729697 0.88 SRC (0.41) NPC1MEN1POLBRAB9AKMT2A
SCHEMBL14729677 0.86 SMN1; SMN2 (0.45) MAOBNPC1MEN1POLBRAB9A
SCHEMBL14729707 0.84 SQOR (0.51) NPC1MEN1POLBRAB9AKMT2A
SCHEMBL14729690 0.84 EGFR (0.45) MAOBLMNAPTGER1KMOSQOR
SCHEMBL14729734 0.83 CNR1 (0.47) NPC1MEN1POLBRAB9AKMT2A
SCHEMBL14729657 0.81 PTGER1 (0.46) MAOBPTGER1
SCHEMBL14729715 0.81 KDM1A (0.46) MAOBNPC1SMN1; SMN2HTTPTGER1
SCHEMBL14729678 0.81 PTGER1 (0.46) NPC1PTGER1KDM1ASQORFEN1
SCHEMBL14729713 0.80 TSHR (0.54) NPC1MEN1RAB9AKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748149-B9 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2017-11-15 EP disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 MAOB 1294/4885NPC1 76/4885MEN1 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.